Device Trial Radar · NCT05506423
Study of the CycloPen Micro-Interventional System and Long-Term Clinical Outcomes
Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Aug 17, 2022
Primary completion
Dec 2026
Study completion Dec 2027
Sponsor
- Lead sponsor
- Iantrek, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 18, 2022
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This observational study will enroll adults with open angle glaucoma (OAG) who had surgery to reduce intraocular pressure (IOP) using the CycloPen Micro-Interventional System. Consenting participants will be followed for 24 months after their surgery. Data regarding IOP, use of glaucoma medications, and any side effects related to the surgery will be collected from participants' preoperative examination, their surgery, and postoperative examinations.
Conditions
- Open Angle Glaucoma
Interventions
CycloPen Cyclodialysis SystemDevice
The CycloPen Micro-Interventional Cyclodialysis System is used to create a cyclodialysis cleft and deliver allograft scleral tissue and/or viscous material within the cleft for endoscleral reinforcement.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent of eyes with intraocular pressure (IOP) reduction ≥ 20% in comparison with baselineTime frame: 12 months postoperative
Locations
16 sites in 2 countries. Site status is shown where the registry gives one.
Visionary Eye Institute
Newport Beach, California
Tyson Eye
Cape Coral, Florida
Central Florida Eye Specialists
DeLand, Florida
13 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.